Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: A meta-analysis

Nephrology Dialysis Transplantation

Volumn 28, Issue 2, 2013, Pages 438-446

  Susantitaphong, Paweena ^a,b,c   Riella, Cristian ^a,b   Jaber, Bertrand L ^a,b  

^a Kidney and Dialysis Research Laboratory   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

AAMI; inflammatory markers; meta analysis; oxidative stress; ultrapure dialysate

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; ENDOTOXIN; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PENTOSIDINE; SERUM ALBUMIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DIALYSATE; DRUG DOSE REDUCTION; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; META ANALYSIS; NUTRITIONAL STATUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ULTRAPURE DIALYSATE;

AGED; ANEMIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIALYSIS SOLUTIONS; FEMALE; HEMOGLOBINS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NUTRITIONAL STATUS; OXIDATIVE STRESS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84874525341     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs514     Document Type: Article

References (75)

1. Rao M, Jaber BL, Balakrishnan VS. Inflammatory biomarkers and cardiovascular risk: association or cause and effect? Semin Dial 2006; 19: 129-135 (Pubitemid 43468645)
2. Balakrishnan VS, Guo D, Rao M et al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 2004; 65: 1449-1460 (Pubitemid 38406987)
3. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001; 59: 407-414 (Pubitemid 32157905)
4. Bommer J, Jaber BL. Ultrapure dialysate: facts and myths. Semin Dial 2006; 19: 115-119 (Pubitemid 43468643)
5. Pereira BJ, Sundaram S, Barrett TW et al. Transfer of cytokineinducing bacterial products across hemodialyzer membranes in the presence of plasma or whole blood. Clin Nephrol 1996; 46: 394-401 (Pubitemid 26421407)
6. Ward RA. Ultrapure dialysate. Semin Dial 2004; 17: 489-497 (Pubitemid 40110435)
7. Masakane I. Review: clinical usefulness of ultrapure dialysate-recent evidence and perspectives. Ther Apher Dial 2006; 10: 348-354 (Pubitemid 44154765)
8. Hsu PY, Lin CL, Yu CC et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients-a prospective cross-over study. J Nephrol 2004; 17: 693-700
9. Lamas JM, Alonso M, Sastre F et al. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements-a randomized study. Nephrol Dial Transplant 2006; 21: 2851-2858 (Pubitemid 44542242)
10. Canaud B, Peyronnet P, Armynot A et al. Ultrapure water: a need for future dialysis. Nephrol Dial Transplant 1986; 1: 110
11. Mion CM, Canaud B, Garred LJ et al. Sterile and pyrogen-free bicarbonate dialysate: a necessity for hemodialysis today. Adv Nephrol Necker Hosp 1990; 19: 275-314
12. Canaud B, Mion CM. Water Treatment for Contemporary Hemodialysis. The Netherlands: Springer, 1996
13. Canaud B, Bosc JY, Leray H et al. Microbiologic purity of dialysate: rationale and technical aspects. Blood Purif 2000; 18: 200-213 (Pubitemid 30619959)
14. Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs 1999; 23: 37-43 (Pubitemid 29047494)
15. Arizono K, Nomura K, Motoyama T et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 2004; 22(Suppl 2): 26-29
16. Honda H, Suzuki H, Hosaka N et al. Ultrapure dialysate influences serum myeloperoxidase levels and lipid metabolism. Blood Purif 2009; 28: 29-39
17. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-1211 (Pubitemid 30487799)
18. Praditpornsilpa K, Tiranathanagul K, Susantitaphong P et al. Effects of different levels of endotoxin contamination on inflammatory cytokine production by peripheral blood mononuclear cells after highflux hemodialysis. Blood Purif 2011; 32: 112-116
19. Schiffl H, Lang SM, Stratakis D et al. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001; 16: 1863-1869 (Pubitemid 32821419)
20. Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096-1101 (Pubitemid 27435845)
21. Canaud B, Bragg-Gresham JL, Marshall MR et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087-2093 (Pubitemid 43924275)
22. Section IV. Dialysis fluid purity. Nephrol Dial Transplant 2002; 17 (Suppl 7): 45-62
23. Kawanishi H, Masakane I, Tomo T. The new standard of fluids for hemodialysis in Japan. Blood Purif 2009; 27(Suppl 1): 5-10
24. Lopes AA, Bragg-Gresham JL, Elder SJ et al. Independent and joint associations of nutritional status indicators with mortality risk among chronic hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Ren Nutr 2010; 20: 224-234
25. Horowitz J, Agarwal A, Huang F et al. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm 2009; 15: 741-750
26. Sharma A, Yee J, Gandra SR et al. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Curr Med Res Opin 2010; 26: 2679-2687
27. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
28. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 (Pubitemid 26120810)
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188 (Pubitemid 17189972)
30. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11: 193-206 (Pubitemid 44001277)
31. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634 (Pubitemid 27387172)
32. Bambauer R, Jutzler GA, Schmidt R et al. Ultrafiltration of dialysis fluid for hemodialysis. ASAIO Trans 1989; 35: 516-519 (Pubitemid 20118288)
33. Bambauer R, Meyer S, Jung H et al. Sterile versus non-sterile dialysis fluid in chronic hemodialysis treatment. ASAIO Trans 1990; 36: M317-M320 (Pubitemid 20367055)
34. Lonnemann G, Schindler R. Ultrafiltration using the polysulfone membrane to reduce the cytokine-inducing activity of contaminated dialysate. Clin Nephrol 1994; 42(Suppl 1): S37-S43 (Pubitemid 24214805)
35. Schindler R, Lonnemann G, Schaffer J et al. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. Nephron 1994; 68: 229-233 (Pubitemid 24289742)
36. Perez-Garcia R, Anaya F, Chisvert J et al. Association of high-flux dialysers and bacterial contamination of dialysate-induced chronic release of cytokines in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 2164-2166
37. Pertosa G, Gesualdo L, Bottalico D et al. Endotoxins modulate chronically tumour necrosis factor alpha and interleukin 6 release by uraemic monocytes. Nephrol Dial Transplant 1995; 10: 328-333
38. Grooteman MP, Nube MJ, Daha MR et al. Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes. J Am Soc Nephrol 1997; 8: 1745-1754
39. Akrum R, Frohlich M, Gerritsen AF et al. Ultrapure water for dialysate contributes to a lower activation state of peripheral blood mononuclear cells. Kidney Int 1999; 55: 1158-1171
40. Schiffl H, Lang SM, Bergner A. Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999; 83: 278-279 (Pubitemid 29486411)
41. Lonnemann G. Should ultra-pure dialysate be mandatory? Nephrol Dial Transplant 2000; 15(Suppl 1): 55-59 (Pubitemid 30114211)
42. Lonnemann G. The quality of dialysate: an integrated approach. Kidney Int Suppl 2000; 76: S112-S119 (Pubitemid 30612810)
43. Schouten WE, Grooteman MP, van Houte AJ et al. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 2000; 15: 379-384 (Pubitemid 30116473)
44. Matsuhashi N, Yoshioka T. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients. Nephron 2002; 92: 601-604
45. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17: 1814-1818 (Pubitemid 35174295)
46. Izuhara Y, Miyata T, Saito K et al. Ultrapure dialysate decreases plasma pentosidine, a marker of 'carbonyl stress'. Am J Kidney Dis 2004; 43: 1024-1029 (Pubitemid 38691497)
47. Furuya R, Kumagai H, Takahashi M et al. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 2005; 23: 311-316 (Pubitemid 41327803)
48. Thome FS, Senger M, Garcez C et al. Dialysis water treated by reverse osmosis decreases the levels of C-reactive protein in uremic patients. Braz J Med Biol Res 2005; 38: 789-794 (Pubitemid 40867520)
49. Zhang P, Chen J, Yuan J. Ultrapure dialysate reduce microinflammation in patients on maintenance hemodialysis by utilizing automatic heat-disinfection RO system. J Am Soc Nephrol 2005 (Abstract
50. Hoenich NA, Ronco C, Levin R. The importance of water quality and haemodialysis fluid composition. Blood Purif 2006; 24: 11-18 (Pubitemid 41820815)
51. Go I, Takemoto Y, Tsuchida K et al. The effect of ultrapure dialysate on improving renal anemia. Osaka City Med J 2007; 53: 17-23
52. Molina M, Navarro MJ, Palacios ME et al. [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving haemodialysis]. Nefrologia 2007; 27: 196-201
53. Ouseph R, Jones S, Dhananjaya N et al. Use of ultrafiltered dialysate is associated with improvements in haemodialysis-associated morbidity in patients treated with reused dialysers. Nephrol Dial Transplant 2007; 22: 2269-2275 (Pubitemid 47244705)
54. Schiffl H, Lang SM. Effects of dialysis purity on uremic dyslipidemia. Ther Apher Dial 2010; 14: 5-11
55. Tao J, Sun Y, Li X et al. Conventional versus ultrapure dialysate for lowering serum lipoprotein(a) levels in patients on long-term hemodialysis: a randomized trial. Int J Artif Organs 2010; 33: 290-296
56. Suzuki H, Honda H, Kato N et al. Assessment of inflow of endotoxin and its fragments in patients on maintenance hemodialysis. Blood Purif 2011; 31: 268-275
57. Rao M, Guo D, Perianayagam MC et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45: 324-333 (Pubitemid 40431059)
58. Bazeley J, Bieber B, Li Y et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2452-2461
59. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148 (Pubitemid 41828276)
60. Owen WF, Jr, Lew NL, Liu Y et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 1001-1006 (Pubitemid 23307908)
61. Kaysen GA, Johansen KL, Cheng SC et al. Trends and outcomes associated with serum albumin concentration among incident dialysis patients in the United States. J Ren Nutr 2008; 18: 323-331 (Pubitemid 351818239)
62. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006; 48(Suppl 1):S2-90
63. Collins AJ, Foley RN, Gilbertson DT et al. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 2009; 4(Suppl 1):S5-11
64. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911 (Pubitemid 29197978)
65. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNFalpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233 (Pubitemid 40463099)
66. Kim Y, MolnarMZ, Rattanasompattikul M et al. Relative contributions of inflammation and inadequate protein intake to hypoalbuminemia in patients on maintenance hemodialysis. Int Urol Nephrol 2012 Apr 15. [Epub ahead of print]
67. Oliva JS, Roa LM, Lara A et al. Survival and factors predicting mortality in hemodialysis patients over 75 years old. J Nephrol 2012 [Epub ahead of print]
68. Rambod M, Bross R, Zitterkoph J et al. Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis 2009; 53: 298-309
69. Streja E, Kovesdy CP, Molnar MZ et al. Role of nutritional status and inflammation in higher survival of African American and Hispanic hemodialysis patients. Am J Kidney Dis 2011; 57: 883-893
70. Panichi V, Rosati A, Bigazzi R et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648
71. Guerrero-Riscos MA, Montes-Delgado R, Seda-Guzman M et al. Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease. Nefrologia 2012; 32: 343-352
72. Administration TUSFaD. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. http://www.fda.gov/Drugs/DrugSafety/ucm259639. htm
73. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098 (Pubitemid 44749317)
74. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
75. Kaysen GA, Dubin JA, Muller HG et al. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58: 346-352 (Pubitemid 30429881)